• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.15% Nasdaq Up0.36%

    Isis Pharmaceuticals, Inc. (ISIS)

    -NasdaqGS
    65.09 Dec 19, 4:00PM EST
    |Pre-Market : 64.00 Down 1.09 (1.67%) 9:28AM EST - Nasdaq Real Time Price
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingDec 31, 2013Dec 31, 2012Dec 31, 2011
    Total Revenue 147,285   102,049   99,086  
    Cost of Revenue -   -   -  
    Gross Profit 147,285   102,049   99,086  
    Operating Expenses
    Research Development184,033  158,458  157,397  
    Selling General and Administrative14,918  12,515  12,789  
    Non Recurring -   -   -  
    Others -   -   -  
    Total Operating Expenses -   -   -  
    Operating Income or Loss (51,666) (68,924) (71,100)
    Income from Continuing Operations
    Total Other Income/Expenses Net4,463  16,895  6,596  
    Earnings Before Interest And Taxes(47,203)(53,435)(68,058)
    Interest Expense19,355  21,152  16,732  
    Income Before Tax(66,558)(74,587)(84,790)
    Income Tax Expense(5,914)(9,109)11  
    Minority Interest -   -   -  
    Net Income From Continuing Ops(60,644)(71,654)(88,355)
    Non-recurring Events
    Discontinued Operations -   -   -  
    Extraordinary Items -   -   -  
    Effect Of Accounting Changes -   -   -  
    Other Items -   -   -  
    Net Income (60,644) (65,478) (84,801)
    Preferred Stock And Other Adjustments -   -   -  
    Net Income Applicable To Common Shares (60,644) (65,478) (84,801)

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.